International companies are increasingly inking licensing deals with China biotechs as concerns regarding drug pricing and ...

BD has found a new home for its biosciences and diagnostics divisions at the lab equipment maker Waters Corporation, through ...

AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based ...

Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

Essa Pharma, which had been resisting pressure from activist investors to wind down operations, has now agreed a deal to ...

Choosing the right specialty pharmacy partner is critical. Especially when you’re treating rare, chronic and complex conditions. You need a partner who delivers more than just logistics management, ...

Takeda is on track to submit its much-hyped narcolepsy drug to regulators this fiscal year after the orexin receptor 2 (OX2R)-selective agonist ...

Karyopharm Therapeutics is laying off 20% of staffers as efforts to secure a strategic alternative have turned up short. | ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

After prematurely ending two phase 3 depression trials last year, Relmada Therapeutics has formally given up on the asset ...

BD has picked a new executive to lead its planned connected care segment, as the company nears the conclusion of its ...

The FDA has released an “initial batch“ of more than 200 complete response letters (CRLs) in efforts to boost transparency. | ...